Zobrazeno 1 - 10
of 95
pro vyhledávání: ''
Autor:
Qingwei Luo, Roberta De Angelis, Nehmat Houssami, Dianne L. O'Connell, Xue Qin Yu, Clare Kahn
Publikováno v:
BMC Cancer
Background Breast cancer places a heavy burden on the Australian healthcare system, but information about the actual number of women living with breast cancer and their current or future health service needs is limited. We used existing population-ba
Publikováno v:
BMC Cancer
Background A signal transduction pathway (STP) is a network of intercellular information flow initiated when extracellular signaling molecules bind to cell-surface receptors. Many aberrant STPs have been associated with various cancers. To develop op
Autor:
Claudia Alessandra Andrade de Paula, Debora Okamoto, Sheila Siqueira Andrade, Mariana Cristina Cabral Silva, Lilian Caroline Gonçalves de Oliveira, Maria Luiza Vilela Oliva, Gil Facina, Giovani B. Peres, Ismael Dale Cotrim Guerreiro da Silva, Tatiana F. Ottaiano, Eloísa Dognani Castro, Antonio Campos, Afonso Celso Pinto Nazário, Edgar J. Paredes-Gamero, Manoel João Batista Castello Girão, Maria A. Juliano, Iuri E. Gouvea
Publikováno v:
BMC Cancer
Background Breast cancer comprises clinically and molecularly distinct tumor subgroups that differ in cell histology and biology and show divergent clinical phenotypes that impede phase III trials, such as those utilizing cathepsin K inhibitors. Here
Publikováno v:
BMC cancer, 16:712. BioMed Central Ltd.
BMC Cancer
BMC Cancer
Background: Response-guided neoadjuvant chemotherapy (RG-NACT) with magnetic resonance imaging (MRI) is effective in treating oestrogen receptor positive/human epidermal growth factor receptor-2 negative (ER-positive/HER2-negative) breast cancer. We
Autor:
Yoko Nakasu, Koichi Mitsuya, Nakamasa Hayashi, Junichiro Watanabe, Hideyuki Harada, Ichiro Ito
Publikováno v:
BMC Cancer
Background Multiple new targeted agents have been developed for patients with human epidermal growth factor receptor type 2 (HER2) – positive breast cancer. Patients with HER2– positive breast cancer will develop brain metastases with greater inc
Autor:
Nicole Lavender, Jiqing Sai, Ann Richmond, Philip Owens, Jinming Yang, C. Andrew Johnson, Gregory D. Ayers, Sheau-Chiann Chen
Publikováno v:
BMC Cancer
Background The role of the chemokine CCL2 in breast cancer is controversial. While CCL2 recruits and activates pro-tumor macrophages, it is also reported to enhance neutrophil-mediated anti-tumor activity. Moreover, loss of CCL2 in early development
Autor:
Xue Qin Yu
Publikováno v:
BMC Cancer
BMC Cancer, Vol 9, Iss 1, p 364 (2009)
BMC Cancer, Vol 9, Iss 1, p 364 (2009)
Background Previous studies have documented lower breast cancer survival among women with lower socioeconomic status (SES) in the United States. In this study, I examined the extent to which socioeconomic disparity in breast cancer survival was expla
Publikováno v:
BMC Cancer
Background Dermatomyositis is an autoimmune myopathy characterized by proximal muscle weakness, muscle inflammation, and typical skin findings. It is a rare disease with an incidence of ~1/100 000. About 15–30 % of adult-onset cases are caused by u
Autor:
Riikka Nurminen, Johanna Schleutker, Heli Nevanlinna, Liisa M. Pelttari, Lauri A. Aaltonen, Alexandra E. Gylfe
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 552 (2012)
BMC Cancer
BMC Cancer
Background Rare, heterozygous germline mutations in the RAD51C gene have been found in breast and ovarian cancer families. In the Finnish population, we have identified two founder mutations in RAD51C that increase the risk of ovarian cancer but not
Autor:
Sandra Salvi, Pier Vitale Nuzzo, L. Zinoli, Francesco Boccardo, Simona Boccardo, Alessandra Rubagotti
Publikováno v:
BMC Cancer
Background PN is a secreted cell adhesion protein critical for carcinogenesis. In breast cancer, it is overexpressed compared to normal breast, and a few reports suggest that it has a potential role as a prognostic marker. Methods Tumour samples obta